Real World Evaluation of Ciltacabtagene Autoleucel (cilta-cel) Toxicity Management: A Single Center Experience

Key Points

• Ciltacabtagene autoleucel treatment is associated with manageable toxicities, and patients show resilient immune responses.
• Observed outcomes include low adverse events, suggesting ciltacabtagene autoleucel is safe for wider application.
• Single center assessment emphasizes the importance of toxicity management protocols to ensure patient safety.
• Management strategies warrant further evaluation across diverse patient populations to enhance treatment efficacy.